Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom S Chan

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Clinical Drug Investigation|December 22, 2021
The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [<sup>14</sup>C]-BI 425809 in Healthy MalesUte Burkard, Michael Desch, Yury Shatillo, et al.
Plos One|June 15, 2018
Upregulation of Krebs cycle and anaerobic glycolysis activity early after onset of liver ischemiaTom S Chan, Shamir Cassim, Valérie-Ann Raymond, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 30, 2021
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 InhibitorMichael Desch, Glen Wunderlich, Markus Goettel, et al.
ALTEX|May 15, 2024
Application of microphysiological systems for nonclinical evaluation of cell therapiesPelin L Candarlioglu, Louise Delsing, Lauren Gauthier, et al.
Pharmacotherapy|December 27, 2024
The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteersXiaofan Tian, Habib Esmaeili, David Minich, et al.
Pharmaceutical Research|June 6, 2023
Characterization of Divergent Metabolic Pathways in Elucidating an Unexpected, Slow-Forming, and Long Half-Life Major Metabolite of IclepertinTom S Chan, Alexander J Byer-Alcorace, Bachir Latli, et al.
Journal of Clinical Pharmacology|December 3, 2014
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlationJohn P Sabo, Jens Kort, Charles Ballow, et al.
Bioconjugate Chemistry|July 2, 2025
Tailoring the Methods of Conjugation and Characterization for a Replication-Competent, Live, Viral VectorElise Ishida, Richard Dambra, Sally Ye, et al.
Advanced Biology|October 9, 2023
Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug DevelopmentLindsay Tomlinson, Diane Ramsden, Sofia Batista Leite, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Clinical Drug Investigation|December 22, 2021
The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [<sup>14</sup>C]-BI 425809 in Healthy MalesUte Burkard, Michael Desch, Yury Shatillo, et al.
Plos One|June 15, 2018
Upregulation of Krebs cycle and anaerobic glycolysis activity early after onset of liver ischemiaTom S Chan, Shamir Cassim, Valérie-Ann Raymond, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 30, 2021
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 InhibitorMichael Desch, Glen Wunderlich, Markus Goettel, et al.
ALTEX|May 15, 2024
Application of microphysiological systems for nonclinical evaluation of cell therapiesPelin L Candarlioglu, Louise Delsing, Lauren Gauthier, et al.
Pharmacotherapy|December 27, 2024
The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteersXiaofan Tian, Habib Esmaeili, David Minich, et al.
Pharmaceutical Research|June 6, 2023
Characterization of Divergent Metabolic Pathways in Elucidating an Unexpected, Slow-Forming, and Long Half-Life Major Metabolite of IclepertinTom S Chan, Alexander J Byer-Alcorace, Bachir Latli, et al.
Journal of Clinical Pharmacology|December 3, 2014
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlationJohn P Sabo, Jens Kort, Charles Ballow, et al.
Bioconjugate Chemistry|July 2, 2025
Tailoring the Methods of Conjugation and Characterization for a Replication-Competent, Live, Viral VectorElise Ishida, Richard Dambra, Sally Ye, et al.
Advanced Biology|October 9, 2023
Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug DevelopmentLindsay Tomlinson, Diane Ramsden, Sofia Batista Leite, et al.
Pageof 4